-
Specialties
Board Certification
American Board of Internal Medicine (Internal Medicine)Patient Rating
5.0 /5( out of 58 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
October 21, 2025HUNTSMAN CANCER CENTERVery considerate in explaining everything in terms a lay person can relate to and learn more as we go.
October 20, 2025HUNTSMAN CANCER CENTERDr Thomas is very professional, kind and compassionate.
October 17, 2025HUNTSMAN CANCER CENTERDr Thomas makes the visit very easy and pleasant and fun as he has a great sense of humor as well as being very informative and positive. He and his team were perfect for my visit
September 18, 2025HUNTSMAN CANCER CENTERDr. Thomas It's a pleasure to work with. He is very caring and clearly an expert in his field and gives me confidence in my care.
September 07, 2025HUNTSMAN CANCER CENTERI loved the time you took to connect with me non-medically. What I'm going through is very scary and to create a brief moment of connection with a brilliant physician like you helps. The mix of technical knowledge and human connection was just right for me. Of course the reason we are there is medicine. This patient appreciates the mix of personal and medicine. Both take time and I'm hoping you'll be able continue that style throughout your career.
September 07, 2025HUNTSMAN CANCER CENTERVery knowledgeable and caring. Took great pains to explain all the details of the disease and treatment. His explanations gave us the information we needed to make our decision without arguing or sounding condescending.
August 30, 2025HUNTSMAN CANCER CENTERI received excellent care from Dr. Thomas.
August 11, 2025HUNTSMAN CANCER CENTERDr Thomas is very understanding! Great bed side manor. Gives all the time you need for questions
August 04, 2025HUNTSMAN CANCER CENTERDr. Thomas is the best doctor I have ever met!
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Assistant Professor (Clinical)
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)Education history
Fellowship Hematology/Oncology - Huntsman Cancer Institute, University of Utah Spencer Fox Eccles School of Medicine Fellow Chief Resident Internal Medicine - University of Connecticut School of Medicine Chief Medical Resident Residency Internal Medicine - University of Connecticut School of Medicine Resident Professional Medical Medicine - Thiruvananthapuram Medical College M.B.B.S. Selected Publications
Journal Article
- Gebrael G, Sahu KK, Chigarira B, Tripathi N, Mathew Thomas V, Sayegh N, Maughan BL, Agarwal N, Swami U, Li H (2023). Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. Cancers (Basel), 15(14). ()
- Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U (2022). Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Eur Urol Focus, 9(1), 106-109. ()
- McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U (2022). Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. Biomedicines, 10(12). ()
- Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N (2022). SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res, 28(22), 4917-4925. ()
- Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7. ()
- Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583. ()
- Mathew Thomas V, Gilreath JA, Newton S, Smock KJ, Lim MY (2021). Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Haemophilia, 27(4), e563-e566. ()
- Singh M, Thomas VM, Mulay S (2020). Bortezomib-induced motor neuropathy: A case report. J Oncol Pharm Pract, 26(6), 1549-1552. ()
- Chango Azanza JJ, Calle Sarmiento PM, Mathew Thomas V, Lopetegui Lia N, Kidwai N (2020). Tumor Lysis Syndrome Caused by Unrecognized Richter's Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression. Cureus, 12(5), e8145. ()
- Mathew Thomas V, Alexander SA, Hadfield MJ, Vredenburgh J (2020). A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure. Cureus, 12(4), e7796. ()
- Alexander SA, Mathew Thomas V, Savage JA (2020). Elevated C-reactive Protein and Role of Steroids in Cocaine-associated Levamisole-induced Vasculitis. Cureus, 12(4), e7597. ()
- Chango Azanza JJ, Mathew Thomas V, Calle Sarmiento PM, Singh M, Alexander SA (2020). Spontaneous Tumor Lysis Syndrome Due to Endometrial Carcinoma. Cureus, 12(3), e7220. ()
- Mathew Thomas V, Bindal P, Ann Alexander S, McDonald K (2019). Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J Oncol Pharm Pract, 26(2), 459-461. ()
- Mathew Thomas V, Alexander SA, Bindal P, Vredenburgh J (2020). Idiopathic Granulomatous Mastitis-A Mystery Yet to be Unraveled: A Case Series and Review of Literature. Cureus, 12(2), e6895. ()
- Mathew Thomas V, Bindal P, Vredenburgh JJ (2019). Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma. Case Rep Oncol, 12(1), 126-130. ()
- Thomas VM, Thomas-Eapen N (2017). An Uncommon Side Effect of a Commonly Used Antibiotic: Amoxicillin-Clavulanic Acid Induced Hepatitis. Korean J Fam Med, 38(5), 307-310. ()
Review
- Mathew Thomas V, Tripathi N, Agarwal N, Swami U (2022). Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. [Review]. Expert Rev Anticancer Ther, 22(4), 335-341. ()
- Thomas VM, Abou-Ismail MY, Lim MY (2021). Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. [Review]. Haemophilia, 28(1), 4-17. ()
Editorial
- Gebrael G, Thomas VM, Swami U, Agarwal N (2022). The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice. Oncologist, 28(9), 746-749. ()
Letter
- Thomas VM, Mathew A (2020). Brain Share, Not Brain Drain. [Letter to the editor]. JCO Glob Oncol, 6, 504. ()
(
out of
58
reviews
)